Bellicum Pharmaceuticals Inc.:
Molecular switch technology and co-stim domains enables pharmacologic control over cells for enhanced efficacy and safety. Lead (registrational EU) program: Ph2 for rivo-cel (alpha/beta addback T-cell therapy for post allogeneic HSTC in non-malignant and malignant diseases). Positive late interim analysis on rivo-cel exp at ASH 2018; full dataset (N=234) exp H1 19. BPX-601: GoCAR-T featuring iMC (inducible MyD88/CD40) activation switch targeting PSCA expressing solid tumors; BPX-701: TCR targeting PRAME.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - West South Central
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy
Website:
Profiles:
Address:
2130 West Holcombe Boulevard, Suite 800
Texas Life Science Plaza
Houston, TX 77030
United States
Texas Life Science Plaza
Houston, TX 77030
United States
Company Participants at Bellicum Pharmaceuticals Analyst and Investor Meeting at ASH
- Rick Fair, CEO
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Bellicum Pharmaceuticals Inc
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 5.39 | 249,123 | 1.88 | 13F | 2020-03-31 |
| Renaissance Technologies LLC | 4.85 | 224,371 | 1.69 | 13F | 2020-03-31 |
| Nikko Asset Management Americas, Inc. | 4.71 | 217,696 | 1.64 | 13F | 2020-03-31 |
| Sumitomo Mitsui Trust Holdings, Inc. | 4.71 | 217,696 | 1.64 | 13F | 2020-03-31 |
| Vanguard Group, Inc. (Subfiler) | 4.03 | 186,307 | 1.40 | 13F | 2020-03-31 |
| The Vanguard Group, Inc. | 3.82 | 176,532 | 1.33 | Funds | 2020-05-31 |
| Frazier Management LLC | 2.27 | 105,144 | 0.79 | 13F | 2020-03-31 |
| BlackRock Institutional Trust Co. NA | 1.81 | 83,798 | 0.63 | 13F | 2020-03-31 |
| Principal Global Investors LLC | 1.01 | 46,790 | 0.35 | Funds | 2020-03-31 |
| Geode Capital Management LLC | 0.89 | 41,155 | 0.31 | 13F | 2020-03-31 |
Top 10 Holders of BELLICUM PHARMACEUTICALS PFD SR 1
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Tavistock Life Sciences Co. (Investment Management) | 948.03 | 5,133,600 | 38.71 | Stakes | 2019-08-16 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.